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ABSTRACT  
When individuals encounter periods of low oxygen, hypoxia, the peripheral chemoreflex works 
to restore saturation to normal levels. The peripheral chemoreceptors are responsible for sensing 
such decreases in oxygen and signaling consequent increases in ventilation and sympathetic-
mediated cardiovascular (CV) responses. Aside from oxygen, other molecules like glucose, 
insulin, leptin, carbon dioxide, and nitric oxide (NO) have been shown to affect this reflex. NO, 
specifically, exhibits a reflex blunting effect demonstrated by various animal studies. Obstructive 
sleep apnea (OSA), a disease characterized by repeated mechanical occlusions of the upper 
airway during sleep, demonstrates both a pathophysiological sensitization of the peripheral 
chemoreflex and a noted decrease in bioavailable NO. This study’s purpose was to analyze the 
effects of acute inorganic nitrate supplementation (beetroot juice), a dietary path for increasing 
bioavailable NO, on the heart rate and ventilatory response to acute hypoxia and brachial blood-
pressure (BP) in subjects with OSA. We hypothesized that, inorganic nitrate would blunt 
chemoreflex responsiveness as observed through the ventilatory and cardiovascular (HR) 
biomarkers. The study followed a double-blind, randomized, placebo-controlled format in which 
14 subjects with mild-to-moderate OSA, over the course of two study days, consumed both the 
placebo beetroot juice (BRP) and the nitrate beetroot juice (BRN;500mg inorganic-nitrate and 
40mg nitrite). Peripheral chemoreflex responsiveness was analyzed as the absolute-change and 
the linear-regression against SpO2 for HR and VE. The ventilatory response was analyzed under 
two criteria: baseline to target 80% hypoxia (Bl-T) and baseline to peak response (Bl-P). The 
effects of BRP and BRN were analyzed as the comparison between the two bouts of acute hypoxia 
(pre-vs-post supplementation) conducted on each study day. The intervention successfully 
increased NO bioavailability (plasma-nitrate: pre:26±11μmol/L , post:292±90μmol/L, p<0.01; 
plasma-nitrite: pre:248±155nmol/L, post:738±427nmol/L, p<0.01). VE responsiveness increased 
in the absolute-change Bl-P-BRP (pre:3.1±1.2L/min, post:4.3±2.3L/min, p=0.03) but  not BRN 
(pre:4.3±2.6L/min, post:4.8±2.7L/min, p=0.43). The VE Bl-T absolute-change (p=0.11), Bl-P 
linear-regression (p=0.33), and Bl-T linear-regression (p=0.08) also did not change. The HR 
response to hypoxia (linear-regression and absolute-change) was unaltered in either intervention 
(p=0.12, p=0.54 respectively). Systolic BP (SBP) increased under BRP (pre:120±9, post:127±10, 
p<0.01), whereas the rise in SBP was not observed with BRN (pre: 123±13 mmHg, post: 123±9 
mmHg, p=0.96), DBP did not change in BRP or BRN (p=0.08). Holistically, these findings 
suggest no impact of nitrate supplementation on peripheral chemoreflex effectors (HR and 
ventilatory response) in OSA. Alternatively, the SBP response to nitrate supplementation may 
suggest inorganic nitrate can blunt diurnal increases in BP.  
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INTRODUCTION 
Obstructive Sleep Apnea: Obstructive sleep apnea (OSA), an increasingly prevalent disease in 
the United States [1, 2], is typified by repeated mechanical occlusions (apneas) of the upper 
airway during nightly sleep. These sleep associated apneas sporadically inhibit ventilation 
leading to periodic bouts of low oxygen (hypoxia) and high CO2 (hypercapnia) [3]. 
Consequentially, individuals with OSA report decreased sleep quality, and sleepiness during 
waking hours [4, 2].  Long term, OSA places individuals at an increased risk for work/motor 
vehicle accidents, depression, metabolic disorders and cardiovascular diseases (CVD): 
hypertension, arrythmias, and stroke [1, 3, 4, 2, 5]. Degrees of severity for this disease are scaled 
according to the apnea hypopnea index (AHI), a metric assessing the average per hour number of 
apneas (ventilatory occlusions lasting more than 10 seconds) and hypopneas (periods of 
decreased airflow which lead to an arterial drop in O2 saturation ≥3% (or periods of decreased 
airflow terminated by neural excitation)) during sleep [3]. Mild, moderate, and severe OSA are 
defined as an AHI of 5-14, 15-29, and 30+ events/hour, respectively [6]. Three major factors 
influence OSA susceptibility: increased collapsibility of the upper airway, decreased function of 
pharyngeal dilators, and irregular ventilation control [7].  Collapsibility is dictated by both the 
skeletal and soft tissue factors which define the length, diameter, and shape of the airway [1, 8]. 
In particular, longer, smaller and certain airway shapes increase one’s risk for OSA. For these 
reasons, Asian (craniofacial structure) and obese (high adiposity) populations show and 
increased prevalence of OSA [9]. 
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OSA and the Peripheral Chemoreflex:  Hypoxia plays a significant role in the 
pathophysiology of OSA. Naturally, the body detects and resolves hypoxic disturbance through 
the carotid (i.e., peripheral) chemoreceptors and physiological effectors of the peripheral 
chemoreflex [4]. More specifically, effectors work to increase bioavailable oxygen by means of 
pulmonary and cardiovascular influence (increased respiratory rate (RR), tidal volume (VT), 
heart rate (HR), and blood pressure (BP)) signaled by increased sympathetic activity and 
parasympathetic withdrawal [4, 10]. Of these physiological adjustments, the ventilatory changes 
are often referred to as the hypoxic ventilatory response, a common marker for peripheral 
chemoreflex activity/sensitivity. In subjects with OSA, peripheral chemoreflex sensitivity is 
potentiated [4]. This may be a consequence of the frequent activation of the reflex during nightly 
hypoxic apneas and the corresponding increased presence of reactive oxygen species (ROS) [2]. 
Additionally, the apneas themselves prevent ventilatory thoracic stretch afferents from inhibiting 
sympathetic outflow leading to unmitigated effector signaling [3]. In general, the overactivity of 
the peripheral chemoreflex in OSA may play a role in OSA’s deleterious pathophysiology [11]. 
 
Nitric Oxide and OSA: Nitric oxide (NO), first discovered in 1987, serves as a vital molecule in 
both bronchodilation and vasodilation [12]. Endogenously mediated by a class of nitric oxide 
synthase enzymes (NOS), NO is produced from the aerobic metabolism of L-Arginine [12, 13]. 
On the vascular level, endothelial NOS (eNOS/NOS III) produces NO when acetylcholine 
signaling drives an increase in intracellular calcium stabilizing NOS’s allosteric activator 
calmodulin [12]. Shear stress on endothelial cells can also increase intracellular calcium through 
action on ion channels, integrins, and G protein-linked receptors [14].  The other NOSs have 
roles in the nervous system (nNOS) and immune response (iNOS) [12]. OSA exhibits a 
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symptomatic decrease in bioavailable NO [15]. Three main components play into this deficit: 
NO oxidative consumption, eNOS disintegration, and asymmetric dimethylarginine (AMDA, 
analog of L-Arginine) inhibition. OSA leads to unmitigated overproduction of ROS leading to 
damage of important macromolecules through oxidative stress [15]. On one level, the presence 
of ROS consumes NO in a chemically favorable reaction that produces the molecule 
peroxynitrite (ONOO-). This “scavenging” of NO can dramatically decrease NO’s bioavailability 
when ROS levels are increased [12]. ONOO- presence also drives uncoupling of the NOS 
enzyme, further decreasing NO production [12]. Additionally, oxidative stress can reduce the 
availability of functionally necessary eNOS subunits, decreasing the normal synthesis of NO 
[15]. Third, AMDA levels, an NOS inhibitor, are elevated in subjects with OSA [15]. While 
most interactions between OSA and NO have been observed at the endothelial level, it must also 
be noted that rats exposed to chronic intermittent hypoxia, a preclinical model of OSA, saw a 
downregulation of nNOS [2]. Thus, a deficit in nNOS may also potentially play into the NO 
deficit in OSA individuals.  
 
The Peripheral Chemoreceptors and Possible Modulators: As mentioned earlier, the 
peripheral chemoreceptors play a key role in regulation of circulatory oxygen levels. More 
specifically, the glomus cells in the carotid bodies are responsible for this sensory role [16, 17]. 
Oxygen related chemosensory discharges from these cells result from the action of the 
constitutively expressed oxygen dependent heme oxygenase 2 (HO-2). When oxygen is present, 
HO-2 metabolizes heme to produce carbon monoxide (CO). During hypoxia, CO levels decrease 
leading to the downstream production of hydrogen sulfide (H2S). H2S in turn drives an increase 
in intracellular calcium leading to chemosensory signaling [17, 18]. Apart from oxygen, other 
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molecules can modulate glomus cell signaling and the coinciding peripheral chemoreflex. Low 
glucose levels (hypoglycemia), high CO2 levels (hypercapnia), high lactate levels, and 
acidification can all stimulate signaling outflow of the glomus cells. Significant evidence also 
exists to support that insulin, leptin, and body temperature can also play roles in carotid body 
stimulus [16]. NO, another molecule that effects glomus cell activity, plays an inhibitory role in 
afferent signaling [16].  
 
Both animal and clinical trials suggest that increasing bioavailable NO may decrease peripheral 
chemoreceptor sensitivity. Tryode dissolved NO profusion of in vitro cat carotid bodies resulted 
in decreases in both frequency and amplitude of chemosensory discharges [19]. Furthermore, 
inhibiting NO production through dosage of nitric oxide synthase blocker, L-NG-nitroarginine 
methyl ester in vivo rats, significantly increased activity in the peripheral end of the carotid sinus 
nerve [20].  
 
The Nitrate-Nitrite-NO Pathway and Nitrate Supplementation: The reduction of dietary 
nitrate in the nitrate- nitrite- NO pathway has been shown to increase NO bioavalibility 
independent of NOS enzymes [21].  In a process known as the enterosalivary nitrate circulation, 
nitrate consumed in the diet passes through most of the upper digestive track and is absorbed into 
the body’s plasma at the proximal small intestine. Accounting for the amount not excreted in 
urine and sweat, blood circulation delivers the remaining 25% of this nitrate to the salivary 
glands where it is concentrated and reduced to nitrite by bacterial reductase enzymes of the oral 
microbiota [13]. Swallowed with saliva, nitrate-derived-nitrite can then progress through a 
number of metabolic processes to yield NO [13]. This natural pathway offers a therapeutic target 
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for mitigating deficits or increasing levels of bioavailable NO through inorganic nitrate 
supplementation.  Specifically, beetroot juice, a supplement high in inorganic nitrate, has been 
shown to increase bioavailable NO presumably by this pathway [21]. In type 2 diabetics, a 
population commonly exhibiting low NO [22], nitrate supplementation produced a significant 
increase in NO bioavailability [21]. Other literature suggests that the therapeutic effects of nitrate 
supplementation can decrease blood pressure. Webb et al. [23] demonstrated that inorganic 
nitrate supplementation (via beetroot juice) significantly decreased both systolic (SBP) and 
diastolic blood pressure (DBP) in young individuals. Furthermore, this lowering effect was 
mitigated when subjects interrupted the enterosalivary reduction by spitting [23]. This BP 
lowering effect seems to be further increased in individuals with hypertension [21]. In a 
randomized clinical trial, Bock et al. [24] demonstrated that four weeks of daily nitrate 
supplementation decreased the hypoxic ventilatory response in older individuals.  These findings 
suggest the blunting of the ventilatory response to hypoxia with inorganic nitrate may serve as a 
possible intervention for the sensitized ventilatory response in individuals with OSA, a 
population with a marked NO deficit [2]. Therefore, we hypothesized that acute inorganic nitrate 
supplementation by way of beetroot juice would attenuate the ventilatory and HR responses to 
acute hypoxia in individuals with OSA.  
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METHODS 
Subjects: The 14 subjects aged between 30-70 with diagnosed mild-to-moderate OSA were 
recruited by means of the University of Iowa’s Sleep Disorders Clinic and enrolled in the study. 
Subjects were excluded if exhibiting symptomatic heart disease, diabetes, autonomic disorders, 
severe OSA (AHI>30), central sleep apnea, kidney disease, allopurinol usage, continuous 
positive airway pressure (CPAP) usage, morbid obesity (body mass index ≥40 kg/m2), hormone 
replacement therapy, or smoking (minimum of six months since cessation). 
Data Collection & Study Day Format: Enrolled subjects, after completing a signed consent 
participated in two separate trial days (cross over design). Over the two trial days, nitrate dosed 
beetroot juice (BRN) (500mg inorganic nitrate and 40mg nitrite), and a placebo beetroot juice 
(BRP, devoid of nearly all nitrate and nitrite) were given in a double-blind randomized order.  
The powdered supplement was administered in 8floz of water. The following outcome measures 
were assessed: HR (three-lead electrocardiogram; Cardiocap Cardiocap/5, Datex-Ohmeda, 
Louisville, CO), resting SBP and DBP (automated brachial cuff; Cardiocap), respiratory rate 
(RR, Hans Rudolph Pneumotachometer, Shawnee, KS), tidal volume (VT, pneumotachometer), 
oxygen saturation (SpO2, finger pulse oximetry, Cardiocap), and end-tidal CO2 (Cardiocap). 
Minute ventilation (VE) was calculated by multiplying VT and RR. Peripheral chemoreflex 
sensitivity was analyzed by regressing HR and VE against SpO2, with all data being binned into 
7-breath averages. The 7-breath average seeks to minimize data variability due to fluctuations in 
individual breaths. Absolute change was assayed for HR and VE under two protocol: baseline to 
peak response and baseline to target hypoxia. For VE, the peak response was recorded as the 
greatest 7 -breath average and the target hypoxia VE represented the last minute of hypoxia. 
Plasma nitrate and nitrite concentrations were gathered from analysis of venous blood samples. 
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Blood was collected before and two hours after beetroot juice consumption in tubes containing a 
lithium heparin anti-coagulant. Plasma separated by centrifugation at 3,000 rpm for 15 minutes 
was frozen in Eppendorf tubes at -80°C until analysis. Thawed samples were combined with a 
vanadium III chloride/hydrochloric acid solution at 90°C and a potassium iodide/acetic acid 
solution at room temperature during chemiluminescence NO analysis (NOA 280i: Sievers 
Instruments, Boulder, CO).  
 
Over the course of each study day, subjects engaged in two rounds of acute isocapnic hypoxia 
(pre- and post-supplementation). Anesthesia gas blender titration of 21% and 10% FiO2 
reservoirs was used to drive oxygen saturations to a target hypoxia (80% SpO2). In addition to 
the reservoir air, a partial rebreathe system aided in balancing carbon dioxide levels while 
providing potential access to ambient air. To prevent central chemoreflex interference on 
outcome measures, reservoir flow rate was titrated according to the end tidal CO2 levels recorded 
at baseline. 
 
The exact timing and outline of subject participation was as follows (Figure 1). The trial days 
began within one week of obtaining the written consent and were separated by a minimum of 
three days to ensure proper washout of the supplement and its metabolites. Each study day 
occurred under a fasted state to prevent dietary interference in variables of interest. Subjects also 
were instructed to abstain from exercise, caffeine, alcohol, COX inhibitors and prescriptions the 
morning of the study.  For the two days prior to each study day, subjects were asked to follow a 
low-nitrate diet.  
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Study days began with a venous catheterization followed by a 15-minute rest period during 
which the first venous blood draw and baseline BP were taken. After setup for the 
pneumotachometer, pulse oximeter, and electrodes for EKG, the first two-minute baseline 
followed under the administration of the 21% O2 reservoir. Post-baseline, the subject’s pulse 
oxygen saturation was lowered to the 80% threshold over the course of 2-5 minutes (variable 
according to inter-subject variability) in the manner discussed above. Measurements were 
continued eight breaths after reaching the 80% threshold and were followed by re-exposure to 
ambient air. After recovery to baseline oxygen saturation, subjects drank the beetroot juice 
supplement and waited two hours for nitrate and nitrate concentration maximums [25]. In the 
manner described above, a second round of acute hypoxia (post-supplementation) after the 
second venous draw and BP measurement.   
Figure 1. Temporal organization of study.  i.v., venous catheter placement; BL, baseline on 21% 
oxygen compressed gas; Hypoxia, acute hypoxic exposure (titrated hypoxic gas to 80%SpO
2
); HR, 
heart rate; VE, minute ventilation. Brachial blood pressure and venous blood draws are denoted by 
↓. * marks consumption of beetroot juice (placebo/nitrate).  
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Statistical Analysis: Data was compared using a repeated measure analysis of variance (RM-
ANOVA) and are reported as mean ± SE (with the exception of demographic data being reported 
as mean ± SD)  In this manner, each set of regressions (HR/SpO2 and VE/SpO2) were compared 
to asses potential significant group (BRP/BRN) by time (pre/post) interactions. Absolute changes 
from baseline to target hypoxia (Bl-T) in HR and VE were also analyzed in this manner. To avoid 
possible under reporting of the ventilatory response due to a nonlinear trend, ventilatory 
regression and absolute change were also analyzed from baseline to peak ventilatory response 
(Bl-P). The effects of BRP and BRN on brachial cuff measures of SBP and DBP were also 
analyzed for a group by time interaction. All significant interactions were further analyzed using 
Tukey’s post-hoc which assessed for between and within group differences. Statistical analysis 
was done at a significance level ≤.05 using Sigma Plot 11.0 (Systat Software Inc., San Jose, 
CA). 
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RESULTS 
 Demographics: Baseline demographics collected on subject’s first study day are displayed in 
Table 1. 18 subjects were recruited for the study, 14 completed the protocol.   
 
 
 
 
 
 
 
 
Inorganic Nitrate Supplementation and Plasma Nitrate and Nitrite: Due to technical 
complications with either venous catheter placement or analysis of blood samples, plasma 
concentrations were not available from all subjects.  Therefore, data presentation reflects the 
following subject numbers for each measured variable:  BRP nitrate and nitrite (n=13), BRN 
nitrate (n=12), and BRN nitrite (n=11). Dietary nitrate supplementation by way of BRN increased 
plasma nitrate and nitrite concentrations (both p<0.01). BRP yielded no change in either nitrate or 
nitrite levels (nitrate: p=0.33, nitrite: p=0.87, Figures 2A and B, respectively). 
Table 1: Research Subject’s Demographic Values (n=14) 
Characteristic: Value 
Age, years 53 ± 10 
Sex, male/female 8/6 
BMI, kg/m2  29.2 ± 5.8 
SBP, mmHg 123 ± 14 
DBP, mmHg 76 ± 9 
MAP, mmHg 91 ± 9 
AHI, events/hr 18.8 ± 7.5 
Nadir SpO2, % 86 ± 3 
Data are means ± SD. BMI, body mass index; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; 
AHI, apnea hypopnea index; Nadir SpO2, lowest SpO2 recorded 
during sleep test.  
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Hemodynamics: Brachial artery SBP and DBP responses to BRN and BRP are shown in Figure 
3. There was an increase in SBP during the BRP condition (p<0.01), whereas SBP did not change 
in the BRN condition (p=0.96, Figure 3A). Furthermore, post SBP was greater in the BRP 
condition compared to BRN. No condition x time interaction was observed for DBP (p=0.08, 
Figure 3B). 
Figure 2. Plasma concentrations of A) nitrate (NO3) and B) nitrite (NO2) before and after 
supplementation of the placebo beetroot supplement lacking nitrate (BRP) or the beetroot 
containing inorganic nitrate and nitrite (BRN). Data are means ± SE. Pre and post reflect baseline 
and two hours after supplementation respectively. † p<0.01 vs pre. * p<.01 vs BRP post. 
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HR responses to hypoxia before and after BRN and BRP are shown in Figure 4. There were no 
condition x time interactions for the HR regression (p=0.12, Figure 4A) or the absolute change in 
HR (p=0.54, Figure 4B). 
Figure 3. A) Systolic and B) Diastolic blood pressure before and after supplementation of the 
placebo beetroot supplement lacking nitrate and nitrite (BRP) and the beetroot containing inorganic 
nitrate and nitrite (BRN). Data are means ± SE. Pre and post reflect baseline and two hours after 
supplementation respectively. † p<0.01 vs pre. *p<0.05 vs. BRN post.  
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Ventilatory Response to Hypoxia: The ventilatory responses to hypoxia are shown in Figure 5. 
There was no condition x time interaction for the Bl-T linear regression (p=0.08, Figure 5A), the 
Bl-T absolute change (p=0.11, Figure 5B), or the Bl-P linear regression (p=0.33, Figure 5C). 
However, the Bl-P absolute change increased in the BRP condition (p=0.03, Figure 5D) but did 
not change in the BRN condition (p=0.43, Figure 5D). 
Figure 4. Heart rate (HR) response before and after supplementation of the placebo beetroot 
supplement lacking nitrate and nitrite (BRP) and the beetroot containing inorganic nitrate and 
nitrite (BRN) in A) HR regression against oxygen saturation and B) absolute change in HR from 
baseline to end hypoxia. Data are means ± SE. Pre and post refer to initial baseline hypoxia and 
the second bout of hypoxia two hours after supplementation.  
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Figure 5. The ventilatory responses to hypoxia expressed as A) VE regression against oxygen 
saturation (SpO2) from baseline to target hypoxia (Bl-T), B) absolute change in VE for Bl-T, C) 
the VE regression against SpO2 from baseline to peak response (Bl-P), and D) the absolute change 
in VE for Bl-P before and after supplementation of the placebo beetroot supplement lacking nitrate 
and nitrite (BRP) and the beetroot containing inorganic nitrate and nitrite (BRN). Data are means ± 
SE. Pre and post refer to initial baseline hypoxia and the second bout of hypoxia two hours after 
supplementation. † p<0.05 vs pre. 
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DISCUSSION 
This study sought to examine the effects of inorganic nitrate supplementation on the sensitivity 
of the peripheral chemoreflex in individuals with OSA. Acute inorganic nitrate supplementation 
substantially increased bioavailable NO in subjects with mild to moderate OSA measured by 
plasma increases in plasma nitrate (1,023%) and nitrite (198%) concentrations (Figures 2A and 
B, respectively). SBP under BRP increased, a change not observed, and possibly mitigated in the 
BRN condition (Figure 3A). DBP did not change in response to either supplementation (Figure 
3B). Generally, the peripheral chemoreflex response to hypoxia, did not vary according to 
supplementation as observed in HR and VE measures (Figures 4 and 5 respectively). Taken, 
together, the hypothesized blunting of the reflex with inorganic nitrate was not supported.   
 
Significant literature suggests that inorganic nitrate supplementation can reduce BP [26]. This 
trend is the largest when examining the decreases in context of SBP (2.3 to 8.9), however it has 
also been observed in reference to DBP (0.2 to 5 mmHg) [26].  While the BP results of our study 
did not follow the documented BP decrease following inorganic nitrate, it does express a 
blunting of a rise in BP due to potential diurnal changes. The temporal fluctuations in BP, or 
diurnal variation, exhibit a strong morning increase and peak associated with wakening and 
increased activity [27]. Other factors such as stress, diet, and smoking can impact the magnitude 
of this phenomena [28]. Study days, all scheduled in the early morning would have observed 
subjects during this diurnal rise, and thus may explain the SBP increase under BRP (Figure 3A). 
The absence of an equivocal rise under BRN hints that nitrate supplementation may play a role in 
mitigating this BP increase. Furthermore, the greater inorganic nitrate blunting of SBP in the 
literature, when compared to DBP, may explain why the mitigation of diurnal rise was only 
16 
 
observed in SBP. It must be noted that this rise is blunted when individuals remain supine 
following waking [28]. Over the course of our study days, subjects spent a significant amount of 
time in a low activity state, at times lying supine. Further compelling this area of study, 
individuals with OSA commonly show irregularities in BP especially in pertinence to the diurnal 
BP cycle. In particular, hypoxic arousals drive an increased nightly BP and may be responsible 
for nondipping nocturnal BP trends. Characterized by a lack of the regular decrease in BP during 
sleep, nondipping BP places individuals at increased risk of CVD and hypertension [29]. 
Pathophysiological prevention of the dipping seen in OSA could be offset by a nitrate induced 
blunting of the morning BP increase in an effort to mitigate overall hypertension. 
 
An increase in HR is a key component of the peripheral chemoreflex in response to hypoxia. For 
individuals with OSA, however, this response to hypoxia is exaggerated. Compared to age and 
BMI matched healthy individuals, Narkiewicz et al. [11] reported that OSA individuals exhibit a 
greater HR response to hypoxia. In the current study, this increased response was not mitigated 
by increasing NO bioavailability by means of inorganic nitrate supplementation (Figure 4). This 
absence of NO blunting on HR translates to the same observation by Bock et al. [24], which 
utilized a longer-term (4-week) inorganic nitrate study in healthy older adults. However, as no 
healthy controls were enrolled in the present study, analyzing the degree of HR response 
augmentation in OSA individuals was not possible. In retrospect, a true control group would 
have allowed us to quantify if the OSA subjects in the current study did indeed have an 
augmented HR response to hypoxia.  
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While significant research has attempted to examine the effects of nitrate on high 
altitude/hypoxic exercise, little work has been done to study its effects on the ventilatory 
response. As mentioned, one long term supplementation study showed a nitrate associated 
decrease in ventilatory response to acute hypoxia for older adults [24]. The current study 
assessed ventilatory response utilizing two analysis techniques, linear regression and absolute 
change, over two temporal criteria, Bl-T and Bl-P. The linear regression was used to quantify the 
rate at which VE changed according to SpO2 while the absolute change simply considered the 
response magnitude. While the regression allowed for a numeric rate analysis, it assumed a linear 
response. However, several subject’s response seemed to progress in a nonlinear fashion (e.g., 
their greatest ventilatory response was not observed at the lowest %SpO2). Additionally, in 
reference to the temporal organization, Bl-P was utilized to avoid underreporting ventilatory 
responsiveness, another consequence of a possible nonlinear relationship. Our results showed no 
impact of either inorganic nitrate or a placebo on VE response except in the BRP Bl-P absolute 
change criteria. However, since no difference was observed in the other three VE analyses 
criteria, it is likely that the low p-value in BRP Bl-P was simply a result of repeated testing. Thus 
holistically, our study saw no decrease in the ventilatory response to hypoxia following inorganic 
nitrate supplementation. As this trend was not seen in this study, two elements must be 
considered: duration of supplementation and effects of OSA morbidity. Unlike Bock et al.’s [24] 
study which followed a daily inorganic nitrate beetroot dosage over four weeks, this study 
utilized an acute supplementation taken during both study days. Thus, reproducing the blunting 
effect in OSA may require a more tonic supplementation approach. Additionally, OSA’s 
physiological consequences may disrupt Bock et al.’s [24] trend which was produced in healthy 
individuals.  
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For this purpose, studying inorganic nitrate supplementation in CPAP competent OSA 
individuals might expose such a relation. CPAP, the most robust available treatment option for 
OSA, successfully blunts pathologically elevated blood pressure (BP), sympathetic nervous 
system activation, and risk of death due to CVD  [2, 3, 5]. Furthermore, CPAP has been shown 
to restore endothelial function (observed by flow mediated dilation), increase circulating NO 
levels, increase levels of substrate L-arginine, and mitigate chemoreflex sensitization in patients 
with OSA [7, 15]. Removing some of the pathophysiological consequences of OSA through use 
of CPAP may allow the inorganic nitrate impact observed in Bock et al.’s [24] study. 
Furthermore, as CPAP is such a functionally robust treatment, inorganic nitrate serves not as a 
replacement option for treating OSA but rather as a possible avenue for an adjunct therapy. 
Future studies should consider including a CPAP competent arm in order to study this possible 
interaction.  
 
In design, there are several distinct limitations to this study. Considering the wide breadth of 
subject demographics, AHI ranged from 5.6 to 29.9 events/hour. AHI and consequently OSA 
severity correlate with sympathetic activation magnitude as well as with hypertension [4, 32]. 
Additionally, in considering BP, one subject in the current study was hypertensive. Literature 
demonstrates that both OSA severity and hypertension correlate with increase peripheral 
chemoreflex sensitivity [3, 8, 11]. Thus, the large variability in AHI and the mixture of 
normotensive, prehypertensive and hypertensive individuals may have increased intersubjective 
variability in response to hypoxia. As the effects of inorganic nitrate on hypoxic response have 
never been assessed in populations with an augmented chemoreflex, it is possible that this 
intervention only yields a therapeutic effect in cases of severe response augmentation. If this 
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where the case, a lack of blunting in milder OSA could obscure significant blunting of the HR 
and VE response in more severe OSA subjects.  Thus, narrowing the demographic breadth to 
populations with greater sensitization may see the proposed therapeutic effects. Future studies 
should consider subpopulations such as hypertensives and/or individuals with severe OSA who 
demonstrate a more robust response to hypoxia [2, 11].  
 
Additionally, because this study looked simply for an interaction between inorganic nitrate 
supplementation and hypoxic responsiveness, only one concentration of nitrate was utilized.  
Literature suggests a dose dependent relationship between inorganic nitrate and cardiovascular 
outcomes. Lara et al. [33] showed increased endothelial function at increased inorganic nitrate 
doses. Additionally, multiple studies have found that inorganic nitrate’s BP lowering effect is 
dose dependent [21]. Accordingly, future studies should consider utilizing multiple 
concentrations of inorganic nitrate to asses for possible dose dependent changes.  
 
Beyond demographics and supplementation considerations, monitoring sympathetic activation 
would further develop our understanding of inorganic nitrate’s impact on OSA. Within the 
peripheral chemoreflex, sympathetic activation plays a key role in effector signaling. As 
discussed earlier, apneas mechanistically facilitate an increase in sympathetic outflow due to the 
inhibition of ventilatory stretch afferents negative regulation of the sympathetic nervous system 
(SNS). Furthermore, in comparison to healthy individuals, SNS activity is increased in OSA [2]. 
This increase is likely due to the repeated activation of the peripheral chemoreflex from nightly 
apneas. Tonic activation of the SNS may ultimately facilitate hypertension, arrythmias, and heart 
failure [2]. Furthermore hypertension, often comorbid with OSA, sees an increased sympathetic 
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response to apnea [3, 27]. Because of its key role in the hypoxic response, future studies 
analyzing the effects of inorganic nitrate supplementation on OSA should consider recording 
sympathetic activation.  
 
Holistically, inorganic nitrate supplementation did not affect the HR and ventilatory response to 
hypoxia. These findings directly contrast several trends observed in the literature (ventilatory 
response blunting and BP lowering). The absence of these trends in the current study suggest a 
lack of a therapeutic effect of inorganic nitrate on the peripheral chemoreflex in OSA. 
Nonetheless, the current study provides support for further consideration of a possible interaction 
between inorganic nitrate and diurnal rise in BP. Further studies should be conducted to analyze 
these trends especially in context of CPAP, and SNS activation.  
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